Supernus Pharmaceuticals Stock Forecast for 2023 - 2025 - 2030

Updated on 02/01/2023

Stock Rating
16
Price Target
$34.00
Consensus
Outperform
Downside
-17.11%
Analysts
0
Stock Rating
16
Downside
-17.11%
Analysts
0
Price Target
$34.00

Supernus Pharmaceuticals Stock Forecast and Price Target

The average target price for Supernus Pharmaceuticals's stock set by renowned analysts in recent months is $34.00, representing a potential downside of approximately -17.11% from its last closing price if met by 2024. This estimation is based on a high estimate of $44.00 and a low estimate of $30.00. If you are interested in SUPN stock, you should also look at its competitors.

$34.00

-17.11% Downside

Outperform
Outperform

Supernus Pharmaceuticals Fair Value Forecast for 2023 - 2025 - 2030

In the last two years, Supernus Pharmaceuticals has seen a decline in its Price, from $28.88 to $13.48 – a 53.33% decrease. In the next year, analysts believe that Fair Value will reach $25.63 – an increase of 90.21%. For the next nine years, the forecast is forFair Value to grow by 130.99%.

2022 Fair Value Forecast
$25.63
2023 Fair Value Forecast
$32.67
2024 Fair Value Forecast
$40.49
2025 Fair Value Forecast
$28.57
2026 Fair Value Forecast
$28.65
2027 Fair Value Forecast
$30.77
2028 Fair Value Forecast
$34.31
2029 Fair Value Forecast
$32.31
2030 Fair Value Forecast
$31.13
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
4502 Stock Forecast Takeda Pharmaceutical Company Outperform 16
¥4.08k Buy/Sell ¥0.00 7.84%
HIK Stock Forecast Hikma Pharmaceuticals PLC Outperform 18
£1.71k Buy/Sell £29.33 -98.39%
ALKS Stock Forecast Alkermes Hold 10
$27.11 Buy/Sell $0.00 18.04%
PBH Stock Forecast Prestige Consumer Healthcare Buy 16
$65.76 Buy/Sell $63.50 3.41%
PCRX Stock Forecast Pacira BioSciences Outperform 16
$39.25 Buy/Sell $79.67 98.73%

Supernus Pharmaceuticals Revenue Forecast for 2023 - 2025 - 2030

Supernus Pharmaceuticals's Revenue has seen growth In the last two years, going from $392.76M to $579.78M – a gain of 47.62% According to the 0 analysts polled, in the next year, Supernus Pharmaceuticals's Revenue will fall by 15.00%, reaching $492.79M. By 2030, professionals believe that Supernus Pharmaceuticals's Revenue will have decreased by 13.20%, falling to $503.27M.

2022 Rev Forecast
$0.49B
2023 Rev Forecast
$0.46B
2024 Rev Forecast
$0.49B
2025 Rev Forecast
$0.52B
2026 Rev Forecast
$0.51B
2027 Rev Forecast
$0.49B
2028 Rev Forecast
$0.49B
2029 Rev Forecast
$0.50B
2030 Rev Forecast
$0.50B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
AMPH Stock Forecast Amphastar Pharmaceuticals Outperform 14
$30.25 Buy/Sell $41.00 45.45%
IRWD Stock Forecast Ironwood Pharmaceuticals Hold 14
$11.52 Buy/Sell $12.60 8.51%
COPN Stock Forecast Cosmo Pharmaceuticals N.V. Buy 12
CHF56.10 Buy/Sell CHF0.00 65.54%

Supernus Pharmaceuticals Dividend per Share Forecast for 2023 - 2025 - 2030

Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
COLL Stock Forecast Collegium Pharmaceutical Buy 11
$28.08 Buy/Sell $27.50 3.28%
NasdaqGS:BDSI Stock Forecast BioDelivery Sciences Internati... - 11
$5.59 Buy/Sell $10.00 78.89%
ANIP Stock Forecast ANI Pharmaceuticals Outperform 13
$42.75 Buy/Sell $61.67 5.26%

Supernus Pharmaceuticals Free Cash Flow Forecast for 2023 - 2025 - 2030

Supernus Pharmaceuticals's Free Cash Flow has decreased In the last two years, from $141.74M to $125.08M – a 11.75% drop. In the next year, analysts are expecting an increase in Free Cash Flow, predicting it will reach $133.68M – an increase of 6.87%. The Supernus Pharmaceuticals forecast is for Free Cash Flow to reach $133.63M or grow by 6.83%.

2022 FCF Forecast
$0.13B
2023 FCF Forecast
$0.14B
2024 FCF Forecast
$0.14B
2025 FCF Forecast
$0.13B
2026 FCF Forecast
$0.13B
2027 FCF Forecast
$0.13B
2028 FCF Forecast
$0.13B
2029 FCF Forecast
$0.13B
2030 FCF Forecast
$0.13B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
EGRX Stock Forecast Eagle Pharmaceuticals Outperform 14
$33.75 Buy/Sell $50.50 43.70%
ENDP Stock Forecast Endo International Underperform 14
$0.41 Buy/Sell $0.00 143.90%
ASRT Stock Forecast Assertio Holdings Outperform 8
$3.74 Buy/Sell $5.83 60.43%

Supernus Pharmaceuticals Net Income Forecast for 2023 - 2025 - 2030

In the last two years, Supernus Pharmaceuticals's Net Income has fallen from $113.06M to $53.42M – a 52.75% decrease. In the next year, analysts predict that Net Income will reach $100.49M – an increase of 88.12%. For the next nine years, the forecast is for Net Income to grow by 126.84%.

2022 NI Forecast
$0.10B
2023 NI Forecast
$0.13B
2024 NI Forecast
$0.16B
2025 NI Forecast
$0.11B
2026 NI Forecast
$0.11B
2027 NI Forecast
$0.12B
2028 NI Forecast
$0.13B
2029 NI Forecast
$0.13B
2030 NI Forecast
$0.12B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
DRRX Stock Forecast DURECT Buy 9
$6.46 Buy/Sell $6.50 -7.12%
ACRX Stock Forecast AcelRx Pharmaceuticals Outperform 6
$0.29 Buy/Sell $4.25 1279.31%
AQST Stock Forecast Aquestive Therapeutics Outperform 0
$2.93 Buy/Sell $0.00 241.30%

Supernus Pharmaceuticals EBITDA Forecast for 2023 - 2025 - 2030

In the last two years, Supernus Pharmaceuticals's EBITDA has seen a drop from $155.23M to $139.49M – a 10.14% decrease. For next year, the 0 analysts predict EBITDA of $170.46M, which would mean an increase of 22.20%. Over the next nine years, the pros' prediction is EBITDAof $173.40M, which would mean a nine-year growth forecast of 24.31%.

2022 EBITDA Forecast
$0.17B
2023 EBITDA Forecast
$0.17B
2024 EBITDA Forecast
$0.19B
2025 EBITDA Forecast
$0.17B
2026 EBITDA Forecast
$0.17B
2027 EBITDA Forecast
$0.17B
2028 EBITDA Forecast
$0.18B
2029 EBITDA Forecast
$0.17B
2030 EBITDA Forecast
$0.17B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
CPIX Stock Forecast Cumberland Pharmaceuticals - 0
$2.23 Buy/Sell $0.00 10.76%
LCI Stock Forecast Lannett Company Hold 10
$0.62 Buy/Sell $2.25 262.90%
ACOR Stock Forecast Acorda Therapeutics - 5
$0.45 Buy/Sell $5.00 11.11%

Supernus Pharmaceuticals EBIT Forecast for 2023 - 2025 - 2030

In the last two years, Supernus Pharmaceuticals's EBIT has gone down from $148.57M to $106.90M – a 28.05% drop. In the next year, analysts expect EBIT to reach $151.43M – an increase of 41.66%. For the next nine years, the forecast is for EBIT to grow by 49.35%.

2022 EBIT Forecast
$0.15B
2023 EBIT Forecast
$0.16B
2024 EBIT Forecast
$0.18B
2025 EBIT Forecast
$0.15B
2026 EBIT Forecast
$0.15B
2027 EBIT Forecast
$0.16B
2028 EBIT Forecast
$0.17B
2029 EBIT Forecast
$0.16B
2030 EBIT Forecast
$0.16B

Supernus Pharmaceuticals EPS Price Prediction Forecast for 2023 - 2025 - 2030

In the last two years, Supernus Pharmaceuticals has seen a decline in its EPS, from $2.10 to $0.98 – a 53.33% decrease. In the next year, analysts believe that EPS will reach $1.86 – an increase of 90.21%. For the next nine years, the forecast is forEPS to grow by 130.99%.

2022 EPS Forecast
$1.86
2023 EPS Forecast
$2.38
2024 EPS Forecast
$2.94
2025 EPS Forecast
$2.08
2026 EPS Forecast
$2.08
2027 EPS Forecast
$2.24
2028 EPS Forecast
$2.50
2029 EPS Forecast
$2.35
2030 EPS Forecast
$2.26